Last reviewed · How we verify
Hepatitis B adjuvanted vaccine — Competitive Intelligence Brief
marketed
Vaccine
Hepatitis B surface antigen (HBsAg)
Immunology
Biologic
Live · refreshed every 30 min
Target snapshot
Hepatitis B adjuvanted vaccine (Hepatitis B adjuvanted vaccine) — GlaxoSmithKline. This vaccine stimulates the immune system to produce antibodies and cellular immunity against hepatitis B virus by presenting hepatitis B surface antigen with an adjuvant that enhances the immune response.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Hepatitis B adjuvanted vaccine TARGET | Hepatitis B adjuvanted vaccine | GlaxoSmithKline | marketed | Vaccine | Hepatitis B surface antigen (HBsAg) | |
| Comirnaty | BNT162b2 (tozinameran) | Pfizer Inc. | marketed | vaccine | SARS-CoV-2 virus | 2021-08-23 |
| Prevnar 20 | pneumococcal 20-valent conjugate vaccine (PCV20) | Pfizer Inc. | marketed | Pneumococcal conjugate vaccine | Streptococcus pneumoniae capsular polysaccharides (20 serotypes) | 2021-06-08 |
| Quadrivalent influenza modRNA vaccine | quadrivalent-influenza-modrna-vaccine | Pfizer | marketed | Vaccine | Influenza virus | |
| batch 1 of Ad5-nCoV | batch 1 of Ad5-nCoV | Jiangsu Province Centers for Disease Control and Prevention | marketed | viral vector vaccine | SARS-CoV-2 spike protein | |
| Hospital-Based Vaccination Pathway | hospital-based-vaccination-pathway | Pfizer | marketed | vaccine | various pathogens | |
| the third batch vaccine | the third batch vaccine | Beijing Chaoyang District Centre for Disease Control and Prevention | marketed | vaccine |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Prevnar 20 · US 8,895,024 · Composition of matter · US
- — Prevnar 20 · US 10,279,033 · Method of use · US
Sponsor landscape (Vaccine class)
- GlaxoSmithKline · 16 drugs in this class
- Sanofi Pasteur, a Sanofi Company · 12 drugs in this class
- Pfizer · 6 drugs in this class
- International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
- Henogen · 3 drugs in this class
- Pfizer Inc. · 2 drugs in this class
- Sanofi · 2 drugs in this class
- Jiangsu Province Centers for Disease Control and Prevention · 2 drugs in this class
- BioNTech · 2 drugs in this class
- Merck Sharp & Dohme LLC · 2 drugs in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Hepatitis B adjuvanted vaccine CI watch — RSS
- Hepatitis B adjuvanted vaccine CI watch — Atom
- Hepatitis B adjuvanted vaccine CI watch — JSON
- Hepatitis B adjuvanted vaccine alone — RSS
- Whole Vaccine class — RSS
Cite this brief
Drug Landscape (2026). Hepatitis B adjuvanted vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/hepatitis-b-adjuvanted-vaccine. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab